The Thrombostat 4000 A Sensitive Screening Test for von Willebrand's Disease

Abstract

The determination of the bleeding time (BT) is an essential diagnostic tool for von WilIebrand's disease (vWD). However, the standardized Simplate ® BT still displays many variables and disadvantages. The present study reports on the sensitivity of the in vitro bleeding test (IVBT) in 51 vWD cases of different types and severity in comparison to the Simplate BT, and the correlation of both to each other as well as to von Willebrand factor (vWF:RCo) activity. The IVBT was performed in two modifications (2 mmoIIL CaCl₂ and 4 mmollL ADP) on the Thrombostat 4000.

The IVBT, particularly with CaCl₂, showed clearly higher sensitivity than the BT (CaCl₂ : 84.3%, ADP: 61.7%, CaCl₂ + ADP: 86.3, BT: 52.9%). The BT even failed in one patient with severe (type 2B) and in three with moderate vWD. The IVBT only failed in very mild forms of the disease (vWF: RCo > 25%). In addition, the IVBT with ADP showed a close correlation to the vWF:RCo activity (r₂ = 0.73). The significantly lower correlation of the BT with vWF:RCo (r₂ = 0.49) was particularly due to the poor results in vWD of type 2 (type 2:r₂ = 0.29; types 1 and 3:r₂ = 0.61). Finally, BT and IVBT-ADP correlated with each other (r₂ = 0.53), a rather good correlation considering that both are complex functional tests. It can be concluded from our study that the IVBT not only may replace the BT for most applications, but is clearly superior to BT for the screening (IVBT-CaCl₂) and control of therapy in vWD.

Keywords

von Willebrand's disease - bleeding time - ristocetin cofactor - Thrombostat 4000 - therapy - von Willebrand's disease

• References

• 1 Kratzer MAA, Born GVR. Simulation of primary haemostasis in vitro. Haemostasis 15: 347-362 1985;
• 2 Kratzer MAA, Belluci S, Caen JP. Detection of abnormal platelet function with an in vitro model of primary haemostasis. Haemostasis 15: 363-370 1985;
• 3 Dietrich G, Weber D, Kretschmer V. The in vitro bleeding test; standardization of the methodical procedure. Lab Med 17: 317-323 1993;
• 4 Kretschmer V, Schikor B, Söhngen D, Dietrich G. In vitro bleeding test—a simple method for the detection of aspirin effects on platelet function. Thromb Res 56: 593-602 1989;
• 5 Sadler JE (for the subcommittee on von Willebrand factor of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis) A revised classification of von Willebrand disease. Thromb Haemost 71: 520-525 1994;
• 6 Weiss HJ, Hoyer LW, Rickles FR, Varma A, Rogers J. Quantitative assay of a platelet factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content. J Clin Invest 52: 2708-2710 1973;
• 7 Ruggeri ZM, Zimmerman TS. Variant von Willebrand's disease. Characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets. J Clin Invest 65: 1318-1325 1980;
• 8 Budde U, Schneppenheim R, Plendl H, Ruggeri ZM, Zimmerman TS. Luminographic detection of von Willebrand factor multimers in agarose gels and on nitrocellulose membranes. Thromb Haemost 63: 312-315 1990;
• 9 Bukh A, Ingerslev J, Stenbjerg S, Hundahl Moller MP. The multimeric structure of plasma VIII F:Ag studied by electroelution and immunoperoxydase detection. Thromb Res 43: 579-584 1986;
• 10 Mielke CH. Measurement of the bleeding time. Thromb Haemost 52: 210-211 1984;
• 11 Ginsburg D, Bowie EJW. Molecular genetics of von Willebrand disease. Blood 79: 2507-2519 1992;
• 12 Italian Working group. Spectrum of von Willebrand's disease: a study of 100 cases. Br J Haematol 35: 101-112 1977;
• 13 Orstavik KH. Genetics of plasma concentration of von Willebrand factor. Folia Haematol (Leipzig) 117: 527-531 1990;
• 14 Gill JS, Endress-Brooks J, Bauer PJ, Marks Jr WJ, Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 69: 1691-1695 1987;
• 15 Weiss HJ. Relation of von Willebrand factor to bleeding time (Letter). N Engl J Med 291: 420 1974;
• 16 Gralnick HR, Rick ME, McKeown LP, Williams SB, Parker RI, Maissonneuve P, Jeanneau C, Sultan Y. Platelet von Willebrand factor: An important determinant of the bleeding time in Type I von Willebrand's disease. Blood 68: 58-61 1986;
• 17 Cattaneo M, Moia M, Valle PD, Castellana P, Mannucci PM. DDAVP shortens the prolonged bleeding times of patients with severe von Willebrand disease treated with cryoprecipitate. Evidence for a mechanism of action independent of released von Willebrand factor. Blood 74: 1972-1975 1989;
• 18 Mannucci PM, Paretti FI, Holmberg L, Nilsson IM, Ruggeri ZM. Studies on the prolonged bleeding time in von Willebrand's disease. J Lab Clin Med 88: 662-671 1976;
• 19 Batlle J, Lopez Fernandez MF, Campos M, Justica B, Berges C, Navarro JL, Diaz Cremades JM, Kasper CK, Dent JA, Ruggeri ZM, Zimmerman TS. The heterogeneity of type IIA von Willebrand's disease: Studies with protease inhibitors. Blood 68: 1207-1212 1986;
• 20 Blatt PM, Brinkhouse KM, Culp HR, Krauss JS, Roberts HR. Antihemophilic factor concentrate therapy in von Willebrand disease. JAMA 236: 2770-2777 1976;
• 21 Pasi KJ, Williams MD, Enayat MS, Hill FGH. Clinical and laboratory evaluation of the treatment of von Willebrand's disease patients with heat-treated factor VIII concentrate (BPL 8Y). Br J Haematol 75: 228-233 1990;
• 22 Cumming AM, Fildes S, Cumming IR, Wensley RT, Redding OM, Burn AM. Clinical and laboratory evaluation of National Health Service factor VIII concentrate (8Y) for the treatment of von Willebrand's disease. Br J Haematol 75: 234-239 1990;
• 23 Kyrle PA, Niessner H, Dent J, Panzer S, Brenner B, Zimmerman TS, Lechner K. IIB von Willebrand's disease: pathogenetic and therapeutic studies. Br J Haematol 69: 55-59 1988;
• 24 Mannucci PM, Tenconi PM, Castaman G, Rodeghiero F. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: A cross-over randomized trial. Blood 79: 313-3137 1992;
• 25 Sakariassen KS, Cattaneo M, vd Berg A, Ruggeri ZM, Mannucci RM, Sixma JJ. DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium. Blood 64: 229236 1984;
• 26 Rodeghiero F, Castaman G, Di Bonna E, Ruggeri M, Lombardi R, Mannucci PM. Hyperresponsiveness to DDAVP for patients with type I von Willebrand's disease and normal intraplatelet von Willebrand factor. Eur J Haematol 40: 163-167 1988;
• 27 Hanna WT, Bona RD, Zimmerman CE, Carta CA, Hebert GZ, Rickles FR. The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease. Thromb Haemost 71: 173-179 1994;
• 28 Gralnick HR, Williams SB, McKeown LP, Rick ME, Maissonneuve P, Jeanneau C, Sultan Y. DDAVP in Type IIa von Willebrand's disease. Blood 67: 465468 1986;